April 13, 2017
Breast cancer is the most common form of cancer amongst women in Canada and worldwide, but despite its prevalence, a group of researchers believes that it should often be treated as a rare disease. Doing so would change clinical approaches and improve treatment for patients.
May 16, 2016
ICGCmed launched this April (see story on ICGCmed’s launch). We spoke to Dr. Peter Lichter, Head of the Division of Molecular Genetics at the German Cancer Research Center (DKFZ) about why ICGCmed is needed and what the next steps are to ensure the consortium can meet its ambitious goals.
Why is ICGCmed necessary, and why now?
Researchers worldwide are currently exploring how to bring more precision oncology to the clinic. The goal is to develop a new approach to how we treat cancer patients that is more specific to their individual type of cancer. Currently, at many places clinical studies are being launched addressing similar questions. An international network of such studies would not only harmonize these initiatives and develop common standards, it would also greatly accelerate the process of validating the concept and provide guidelines to physicians who are not yet familiar with this approach.